Nu kommer den første vaccine mod humant papillomvirus

Susanne Krüger Kjaer; Frede Olesen; Kim Toftager-Larsen; Carsten Sand; Gitte I Strauss; Thomas U Hoffmann; Bent S Ottesen

Nu kommer den første vaccine mod humant papillomvirus

Translated title of the contribution: The first HPV vaccine is now available

Susanne Krüger Kjaer
, Frede Olesen
, Kim Toftager-Larsen
, Carsten Sand
, Gitte I Strauss
, Thomas U Hoffmann
, Bent S Ottesen

2 Citations (Scopus)

Abstract

More than two thirds of carcinomas of the uterine cervix are caused by human papilloma virus (HPV) types 16 and 18, and 90% of all genital warts are caused by HPV 6 and 11. In June 2006, the US Food and Drug Administration accepted the first prophylactic HPV vaccine against HPV 6, 11, 16 and 18 to be offered to girls and young women. This new vaccine is also now available in Denmark. Questions concerning economics, ethics, organization, and vaccine monitoring need to be discussed in connection with the establishment of a vaccine program. In addition, information to the general population as well as to health care providers and decision-makers should have been given a high priority.

Translated title of the contribution	The first HPV vaccine is now available
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	168
Issue number	44
Pages (from-to)	3827-8
Number of pages	2
ISSN	0041-5782
Publication status	Published - 30 Oct 2006
Externally published	Yes

Cite this

@article{f38ef9a0da264eaa9edfd6daef3fe72d,

title = "Nu kommer den f{\o}rste vaccine mod humant papillomvirus",

abstract = "More than two thirds of carcinomas of the uterine cervix are caused by human papilloma virus (HPV) types 16 and 18, and 90\% of all genital warts are caused by HPV 6 and 11. In June 2006, the US Food and Drug Administration accepted the first prophylactic HPV vaccine against HPV 6, 11, 16 and 18 to be offered to girls and young women. This new vaccine is also now available in Denmark. Questions concerning economics, ethics, organization, and vaccine monitoring need to be discussed in connection with the establishment of a vaccine program. In addition, information to the general population as well as to health care providers and decision-makers should have been given a high priority.",

keywords = "Adolescent, Child, Denmark, Female, Humans, Immunization Programs/economics, Male, Papillomavirus Infections/complications, Papillomavirus Vaccines/administration \& dosage, Uterine Cervical Neoplasms/prevention \& control",

author = "Kjaer, \{Susanne Kr{\"u}ger\} and Frede Olesen and Kim Toftager-Larsen and Carsten Sand and Strauss, \{Gitte I\} and Hoffmann, \{Thomas U\} and Ottesen, \{Bent S\}",

year = "2006",

month = oct,

day = "30",

language = "Dansk",

volume = "168",

pages = "3827--8",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske L{\ae}geforening",

number = "44",

}

TY - JOUR

T1 - Nu kommer den første vaccine mod humant papillomvirus

AU - Kjaer, Susanne Krüger

AU - Olesen, Frede

AU - Toftager-Larsen, Kim

AU - Sand, Carsten

AU - Strauss, Gitte I

AU - Hoffmann, Thomas U

AU - Ottesen, Bent S

PY - 2006/10/30

Y1 - 2006/10/30

N2 - More than two thirds of carcinomas of the uterine cervix are caused by human papilloma virus (HPV) types 16 and 18, and 90% of all genital warts are caused by HPV 6 and 11. In June 2006, the US Food and Drug Administration accepted the first prophylactic HPV vaccine against HPV 6, 11, 16 and 18 to be offered to girls and young women. This new vaccine is also now available in Denmark. Questions concerning economics, ethics, organization, and vaccine monitoring need to be discussed in connection with the establishment of a vaccine program. In addition, information to the general population as well as to health care providers and decision-makers should have been given a high priority.

AB - More than two thirds of carcinomas of the uterine cervix are caused by human papilloma virus (HPV) types 16 and 18, and 90% of all genital warts are caused by HPV 6 and 11. In June 2006, the US Food and Drug Administration accepted the first prophylactic HPV vaccine against HPV 6, 11, 16 and 18 to be offered to girls and young women. This new vaccine is also now available in Denmark. Questions concerning economics, ethics, organization, and vaccine monitoring need to be discussed in connection with the establishment of a vaccine program. In addition, information to the general population as well as to health care providers and decision-makers should have been given a high priority.

KW - Adolescent

KW - Child

KW - Denmark

KW - Female

KW - Humans

KW - Immunization Programs/economics

KW - Male

KW - Papillomavirus Infections/complications

KW - Papillomavirus Vaccines/administration & dosage

KW - Uterine Cervical Neoplasms/prevention & control

M3 - Tidsskriftartikel

C2 - 17118245

SN - 0041-5782

VL - 168

SP - 3827

EP - 3828

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 44

ER -

Nu kommer den første vaccine mod humant papillomvirus

Abstract

Fingerprint

Cite this